4093-28-1Relevant articles and documents
Methyl 4-acetamido-2-butoxybenzoate derivatives as well as preparation method and application thereof
-
Paragraph 0007; 0022; 0023, (2020/08/03)
The invention relates to methyl 4-acetamido-2-butoxybenzoate derivatives as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry. The structural formula of the methyl 4-acetamido-2-butoxybenzoate derivatives is shown in the specification, wherein R1 is alkyl, substituted phenyl, heteroaromatic ring group or substituted styryl; and R2 is fatty aminoor benzylamino. The preparation method is simple and high in yield. Most compounds provided by the invention have good influenza virus neuraminidase inhibition activity.
Preparation method of ethopabate
-
Paragraph 0022; 0024, (2018/04/01)
The invention discloses a preparation method of ethopabate. Initially, para-aminosalicylic acid and p-toluene sulfonic acid are dissolved in methanol to form a mixed solution, the mixed solution is put in a reaction bottle, evenly stirred and heated, and a thermal insulation reaction is carried out; sodium acetate is added into a methyl p-aminosalicylate reaction liquid, the pH and temperature ofthe reaction liquid are controlled, acetylase is added, and a reaction is carried out to obtain methyl p-acetaminosalicylate; methyl p-acetaminosalicylate is added into acetone, heating is carried out, diethyl sulfate is added dropwisely, and after adding dropwisely is completed, a reaction is carried out to obtain ethopabate. The method has the advantages that industrial production can be achieved, resource conservation and environmental protection can be achieved, the cost can be better saved, the product quality is stable, the yield is high, and the method is suitable for large-scale industrial stable production.
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 0955; 0956; 0957, (2016/09/26)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.